English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
The Rise of Psychedelic Biotech: What It Means for Plant Medicine Seekers
Something strange is happening in the world of psychedelics. While shamans in the Amazon still brew ayahuasca over wood fires the same way they have for centuries, men in suits in London and Boston are quietly raising tens of millions of dollars to turn psilocybin, 5-MeO-DMT, and LSD into prescription medications. Both worlds are circling the same molecules. Both claim to be doing it for the same reason — to help people who haven’t been helped by anything else. If you’re sitting at your laptop right now wondering whether to book a psychedelic retreat, this matters more than it might look. The biotech boom is reshaping which substances get studied, which get legalized, and ultimately which ones you’ll be able to access — whether through a clinic, a retreat center in Peru, or eventually a doctor’s office. So let’s look at what’s actually going on, and what it means for someone weighing plant medicine as a path through depression, trauma, or addiction. For most of the last fifty years, psychedelics were a research dead zone. Schedule I status in the U.S., similar restrictions in Europe, and a generation of scientists who learned to keep quiet if they wanted tenure. Then around 2010, things started shifting. Imperial College London began running careful psilocybin studies. Johns Hopkins published results that were genuinely hard to dismiss. MAPS pushed MDMA through Phase 3 trials for PTSD. Investors noticed. By 2020, a handful of UK and North American companies had raised serious money to develop psychedelic-based pharmaceuticals. One of them — Beckley Psytech, an offshoot of the long-running Beckley Foundation that has partnered on psychedelic research for over two decades — closed an $18.6 million funding round to begin clinical trials of 5-MeO-DMT, the powerful psychedelic found in the secretions of the Sonoran Desert toad (and also synthesized in labs, which is what they actually use). Their pitch is straightforward. There’s a clear unmet need in mental health. Antidepressants help some people, sort of, some of the time. Around a third of people with major depression don’t respond to standard treatments at all. Psychedelics, in early trials, are showing response rates that make pharmaceutical executives sit up and call their accountants. Companies in this space tend to think about psychedelics in three tiers, and it’s a useful frame even if you’re not an investor. For retreat seekers, the interesting tension is in tiers one and two. The same molecules being patented and clinicalized in Oxford and Cambridge are the ones already being served in maloca ceremonies in the Sacred Valley. The setting is wildly different. The molecule is the same. Honest answer: both, depending on the day you ask me. On one hand, large-scale clinical trials are giving cultural legitimacy to substances that healers in the Amazon, Mexico, and Gabon have been working with for generations. When Johns Hopkins publishes a study showing psilocybin produces lasting improvements in treatment-resistant depression, it makes it easier for a 45-year-old accountant in Ohio to consider that maybe a mushroom ceremony isn’t a fringe idea. It softens the stigma. It opens doors. On the other hand, the pharmaceutical model and the ceremonial model want very different things. A drug company needs a standardized molecule, a fixed dose, a measurable outcome, and a process that can be repeated identically in clinics around the world. A traditional ayahuasca ceremony is the opposite — a brew whose strength varies between batches, a curandero singing icaros that respond to the room, a healing process that depends on context, lineage, and relationship. Both can work. They’re not the same thing. And anyone telling you the clinical version makes the ceremonial version obsolete is selling something — usually shares in a biotech startup. Here’s the practical part. If you’re researching ayahuasca, psilocybin, ibogaine, or any other plant medicine because something in your life isn’t working — depression that won’t lift, addiction that won’t loosen, a trauma that keeps replaying — the biotech news is mostly background noise for your decision today. Approved psychedelic medications aren’t broadly available yet. Companies talk about 2026 or 2027 timelines, which usually means 2028 or later. Spravato (esketamine, a ketamine derivative) is the closest thing already on shelves, and it has its own limitations. If you need something now, your realistic options are: The retreat path isn’t for everyone, and I want to be straight about that. It’s not cheap (expect $1,500 to $5,000 for a quality week-long program, sometimes much more). It requires real preparation — diet changes, medication reviews, emotional readiness. And it has real risks, especially for anyone with a personal or family history of psychosis or certain cardiac conditions. The flood of money into psychedelics has also flooded the retreat space with new operators, some excellent, some not. A few things worth checking before you wire a deposit: The fact that respected scientists, multibillion-dollar funds, and pharmaceutical executives are now taking psychedelics seriously is, on balance, a good development for anyone who cares about mental health. It means more research, safer access, eventual insurance coverage, and a slow loosening of laws that have kept these tools locked away from the people who needed them most. But it doesn’t replace what happens in a ceremony at midnight in the jungle, when an icaro slips under your skin and something old in you finally cracks open. The clinical version and the traditional version are likely to coexist for a long time. They serve overlapping but distinct purposes. Some people will find what they need in a sterile office with a therapist and a fixed dose. Others will find it on a mat in a maloca with a curandero who has been doing this since before they were born. If any of this resonates and you want to look at real options rather than abstract possibilities, a curated selection of ayahuasca and plant medicine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine isn’t going anywhere, and neither is the part of you that’s ready to do this work.
Why Set and Setting Break the Standard Psychedelic Drug Trial
There's a strange thing that happens when scientists try to study psychedelics the way they study aspirin. The experiment looks clean on paper — give one group the molecule, give another group a sugar pill, measure the difference. But anyone who's actually sat through a ceremony, or even read a few honest trip reports, knows the molecule is maybe half the story. The room matters. The music matters. Who's sitting next to you matters. Whether you spent the morning meditating or arguing with your landlord matters. This is the quiet problem at the heart of modern psychedelic research, and it's one that anyone considering a retreat should understand. Because if the science can't fully capture what these substances do, then the way you set up your own experience — the people, the place, the intention — is doing a lot more of the work than the white-coat literature lets on. From the late 1940s through the 1960s, there was a genuine boom in psychedelic research. Thousands of papers. LSD studied for alcoholism, anxiety in terminal cancer patients, obsessive thinking, even creativity in engineers. Some of it was rigorous, some of it was loose, and a lot of it was lost when the Controlled Substances Act of 1970 effectively shut the field down. For roughly two decades, serious clinical work on psychedelics and master plants more or less stopped. Things began to thaw in the 1990s. Today there are clinical trials at major universities studying psilocybin for depression, MDMA for PTSD, and ibogaine for opioid addiction. Plant medicine has gone from fringe to the cover of mainstream magazines. Yet the methodology hasn't changed much. The placebo-controlled trial — randomize, blind, compare — is still the regulatory gold standard. And that's where the cracks start to show. The logic is straightforward and, for most drugs, sound. You isolate the variable. Everyone gets the same pill-shaped object, nobody knows who got the real thing, and any difference in outcome between the two groups is attributable to the molecule itself. It works beautifully for statins. It works for antibiotics. It works for almost anything where the drug's job is to do a discrete biochemical thing in the body and the patient's mental state is largely irrelevant. Psychedelics don't behave like that. The molecule kicks open a door, but what walks through depends enormously on the room you're standing in. Timothy Leary gets credit for popularizing the phrase “set and setting,” though the underlying idea was floating around in psychiatry well before him. Set is what you bring in — your mood, your history, your expectations, your unresolved stuff. Setting is everything around you — the physical space, the people present, the sounds, the smells, the cultural framing. A few studies have probed this in concrete ways. Researchers interviewing nearly a hundred MDMA users found that the bad experiences clustered around specific predictors: a sour mood going in, anxiety about the source, watching a friend have a rough time. Another small study from the mid-1970s tracked cannabis smokers in friendly versus neutral environments and found that the same dose produced noticeably different subjective reports depending on the vibe of the room. And work on the UK rave scene of the late 1980s suggested that the music itself — particularly the repetitive drumming — was doing real work in shaping the altered state. None of this is mystical. It's just an honest accounting of how these molecules interact with a human nervous system, which is never operating in a vacuum. Take a beta-blocker in a sterile lab, take it on a beach, take it in your grandmother's kitchen — your heart rate is going to do the same thing. Take psilocybin in those three places and you may have three radically different afternoons. The drug doesn't just produce an effect; it amplifies and refracts whatever is already in the room, including what's in your head. This is exactly why traditional Amazonian ayahuasca practice spends so much energy on what Westerners would call “setting.” The icaros, the diet, the seclusion, the order of the night — these aren't decorative. They're the technology that shapes the experience. Strip them away and you have the same brew, but a very different ceremony. Some researchers have suggested moving toward what they call “culture-controlled” trials. Instead of trying to neutralize setting, you systematically vary it and study what happens. Imagine the same dose of MDMA given to one group in a clinical office and another at a carefully held therapeutic retreat, with all the difference that implies — couches, blankets, eye masks, curated music, a therapist who knows what they're doing. You'd learn something the placebo design literally cannot show you. This isn't anti-science. It's a more honest science, one that matches the methodology to the actual phenomenon. Drugs that work primarily through consciousness need to be studied with consciousness in the frame. Here's the practical translation, because this is where the abstract debate lands in your real life. If setting is doing a huge share of the work, then the retreat you pick isn't a minor detail — it's arguably the most important variable you control. A few things worth weighing: None of this guarantees a transformative experience. Plant medicine is not a vending machine. But the literature on set and setting, taken seriously, tells you that putting effort into these choices isn't optional fussing — it's most of the work. The placebo-controlled trial gave us modern medicine, and it's not going anywhere. But psychedelics are revealing the edges of that model, and the field is slowly, sometimes grudgingly, figuring out how to study substances whose effects are inseparable from context. For now, the official science will keep producing useful but partial answers, and the deeper truths about psychedelic healing will continue to live in the spaces between the data — in maloca floors, retreat kitchens, the hour after a ceremony ends, the months of integration that follow. For readers who want to take this further, a range of carefully curated ayahuasca and plant medicine retreats can be browsed on our marketplace here. Pick your setting with the same care the medicine deserves.
Life After Ibogaine: Why Your Post-Treatment Plan Matters More Than the Flood
There's a quiet truth in the ibogaine world that nobody puts on the brochure: the medicine doesn't do the work. It opens the door. What happens after you walk through it — the weeks and months when you're back home, back in your kitchen, back in your old life — is where the actual healing lives or dies. And most people, including most people running clinics, don't talk about this part nearly enough. If you're researching ibogaine for addiction recovery, depression, or some other stubborn pattern you can't seem to outrun, this is the piece I wish someone had handed me before I booked a thing. Not the success stories. Not the trip reports. The plan. Because the plant medicine itself is only the first act. Ibogaine is a long-acting psychedelic alkaloid from the iboga root, used traditionally in Bwiti ceremonies in Gabon and, more recently, in clinical settings for opioid dependence and other addictions. A full session can last 24 to 36 hours. People describe a dreamlike review of their life, sometimes brutally honest, sometimes tender, sometimes both in the same five minutes. Here's what it tends to do well: it interrupts withdrawal from opioids in a way nothing else really does, it loosens the grip of compulsive patterns, and it gives many people a few weeks of unusual clarity afterward — what some clinicians call the afterglow or the window. That window is real. It's also temporary. What ibogaine doesn't do: rebuild your relationships, find you a new job, teach you how to feel boredom without reaching for something, or replace the friends who only know you as the version of you that used. None of that comes in the capsule. If you treat the session like a cure, you'll be disappointed within three months. If you treat it as the most powerful tool you've ever been handed for the work you still have to do — that's where the change happens. For roughly four to twelve weeks after a session, many people report a noticeable shift. Cravings are quieter. Old triggers feel further away. There's a softness, sometimes a strange grief, sometimes a surge of motivation. Your nervous system is, in essence, recalibrating. This window is gold. It's also the easiest thing in the world to waste. People waste it in predictable ways. They go back to the same apartment, the same routines, the same five friends, and assume the new feeling will hold on its own. It rarely does. The mind has a long memory for habit, and the second the afterglow fades — and it does fade — the old grooves are still right there waiting. The people I've watched genuinely change their lives after ibogaine all did something during that window. They moved. They quit a job. They started therapy. They cut off three numbers. They picked up a daily practice and stuck with it past the point where it was novel. The medicine gave them traction; they used it to climb. A good integration plan isn't a vision board. It's a list of specific, concrete things you've already committed to before you ever sit down for the session. Vague intentions evaporate. Calendar entries don't. Here's the shape of one that actually works: None of this is glamorous. None of it involves a second ceremony. That's the point. The most common post-ibogaine failure I've seen isn't relapse in the dramatic sense. It's something quieter: people get so attached to the experience itself that they keep chasing the next session instead of metabolizing the one they already had. Six months later they're booking iboga number three and they still haven't called the therapist. Plant medicines can become their own kind of bypass. The trip becomes the identity. The retreat becomes the vacation from your actual life. If you find yourself planning the next ceremony before you've done anything with the last one, that's worth paying attention to. The work was never the medicine. The work is Tuesday morning at 9 a.m. when nobody's watching. This isn't an argument against multiple sessions — some people genuinely benefit from them, spaced out over years. It's an argument against using ceremony as a way to avoid the slow, unsexy labor of changing how you live. If you're still in the research phase, here's a filter that will eliminate maybe sixty percent of options instantly: ask the provider what their post-treatment support looks like. A serious clinic or facilitator will have a real answer — integration calls, a structured follow-up program, a network of aftercare resources, ideally a relationship with therapists or coaches they refer to. A sketchy one will say something like "we send you home with intentions" and change the subject to deposit policies. Other questions worth asking before you commit: If the answers feel rehearsed or evasive, walk. The plant-medicine space has both genuine healers and people who learned the right vocabulary last year. You're trusting them with your nervous system for thirty-something hours. Due diligence isn't paranoid; it's the bare minimum. Nobody warns you about the airport. You step off the plane after a week in the jungle or at a clinic somewhere, and the world is exactly as you left it. Same advertisements. Same traffic. Same people who don't know what you've just been through and wouldn't entirely understand if you tried to explain. This re-entry is harder than the session for a lot of people. Plan for it. Don't schedule a giant work week the day after you land. Don't expect your partner to immediately understand the version of you that came back. Give yourself a few days of soft landing — quiet, nature, simple food, no big decisions — before you try to slot back into normal life. And keep talking about it, in the right contexts. Integration groups exist online and in person specifically because most of the people in your daily life are not equipped to hold what you're processing. That's not a judgment of them. It's just true. Find the rooms where it makes sense to speak honestly. Ibogaine, at its best, is a lever. It moves things that wouldn't otherwise budge. But a lever needs something to push against, and that something is the life you build in the months and years after. The people I know who are five or seven years out from a session that genuinely changed them all say some version of the same thing: it was the start, not the finish. The work didn't end when the visions stopped. If you're considering this path for addiction, trauma, or a depression that hasn't responded to anything else, take the choice seriously — both the choice to go, and the choice of what to do when you come back. The session is one weekend. The aftercare is the next two years. Build for that. For readers who want to take this further, a range of vetted ibogaine and plant-medicine retreats with integration support can be browsed on our marketplace here.
Big Money Meets Psychedelics: What Pharma Investment Means for Plant Medicine Seekers
A few years back, the idea that a serious pharmaceutical company would raise hundreds of millions of dollars to turn psilocybin and ibogaine into prescription medicines would have sounded faintly ridiculous. Now it's just a Wednesday. Biotech platforms backed by Peter Thiel and old-money family offices are writing nine-figure checks toward psychedelic-assisted therapy. And if you're someone quietly researching ayahuasca, psilocybin, or ibogaine as a way out of depression, addiction, or trauma, this matters more than it might seem. Because the world of psychedelics is splitting into two tracks. One is the clinical-pharma path — synthesized compounds, white-coat protocols, FDA trials. The other is the older path most retreat-seekers are actually looking at — ceremonies, master plants, facilitators with twenty years in the jungle. Knowing the difference helps you make a smarter decision about where to put your money and your nervous system. A biotech outfit called atai Life Sciences closed a Series D financing round of roughly $157 million a few years back, on top of a $125 million round only months earlier. That put their total raise north of $350 million — the kind of money that, until recently, never went near anything involving DMT or iboga bark. The investors weren't fringe believers either. Thiel Capital, large healthcare-focused equity funds, the usual constellation of family offices and venture firms. atai's model is essentially a holding company for psychedelic drug development. They take stakes in subsidiaries working on synthetic psilocybin, arketamine, ibogaine, and a handful of non-psychedelic compounds. The flagship bet is their stake in Compass Pathways, which has been running phase II trials of a synthesized psilocybin formulation for treatment-resistant depression. That's the company that went public on the NASDAQ and basically opened the floodgates for institutional money to take this stuff seriously. The CEO at the time, Florian Brand, said something honest about why they're spreading bets across multiple compounds: no single molecule is a cure-all, and mental health is wildly heterogeneous. Depression in one person doesn't look like depression in another. PTSD has fingerprints. Addiction has its own neurochemistry. So instead of betting the farm on psilocybin alone, they're building what he called a toolbox. Fair question. You're not buying stock. You're trying to figure out whether to fly to Peru, or Costa Rica, or rural Oregon, and drink something that might dismantle your worldview for six hours. What does atai's balance sheet have to do with any of that? Three things, actually. Here's the thing nobody really tells you. The synthesized psilocybin being trialed in clinics is, chemically, the same active molecule found in magic mushrooms. But the context surrounding the molecule changes the experience profoundly. In a clinical setting you get a measured dose in a quiet room, often with eyeshades and curated music, a licensed therapist present, and structured integration sessions. It's controlled, predictable as these things can be, and increasingly evidence-based. The downside? It's expensive, gated by diagnosis, and stripped of the cultural and spiritual scaffolding that humans have used around these substances for thousands of years. A traditional ayahuasca ceremony or San Pedro ceremony is the opposite of clean. You'll sit through hours of icaros, songs sung by curanderos who've been training since adolescence. The brew tastes like swamp water that's been crying. You may purge. You may cry. You'll likely meet things — your own grief, your dead grandmother, the architecture of your shame — that no clinical protocol is built to hold. The container is older and stranger, and for many people, it's exactly what the work demands. Neither path is universally better. But they answer different questions. If you want symptom relief inside a medical framework, the pharma route, once approved, will be your option. If you're after what people in this world call soul exploration — the messy, meaning-laden, sometimes terrifying confrontation with your own depths — that's still mostly what retreats are for. You'll see the phrase "master plants" a lot in retreat literature, and it's worth understanding what's meant. In Amazonian traditions, a master plant — or planta maestra — is a plant considered to have a spirit, a teacher-quality, an intelligence that can transmit knowledge to someone who diets with it properly. Ayahuasca is the most famous, but the category includes tobacco (in its ceremonial form, mapacho), chacruna, bobinsana, ajo sacha, chiric sanango, and many others. A traditional dieta involves isolating with one of these plants for days or weeks, eating bland food, abstaining from sex, salt, sugar, and most stimulation, and drinking preparations of the plant under a curandero's guidance. The point isn't recreational. It's to learn from the plant. Whether you take that framework literally as spirit-communication or metaphorically as deep neurochemical attunement, the practice produces effects that participants describe in remarkably consistent ways across generations. This is what biotech can't really package. The molecule isolated from the vine is one thing. The relationship cultivated through dieta is another. Both can be useful. They are not interchangeable. Money in the space is mostly good news. It also means more marketing, more slick websites, more retreats opening because someone smelled an opportunity rather than because someone trained for twenty years. So a few honest things to think about before you wire a deposit anywhere. Since this is where a lot of readers are quietly coming from — yes, the research on psychedelics for addiction is genuinely promising. Ibogaine has shown striking results in interrupting opioid dependence, with people reporting that withdrawal collapses in hours and cravings stay diminished for weeks or months. Psilocybin has produced encouraging numbers in smoking cessation and alcohol use disorder trials. Ayahuasca has a long indigenous history of being used to address what we'd now call substance dependence, and the modern data is beginning to catch up. But — and it's an important but — none of these are a one-and-done miracle. The people who get durable benefit almost universally do the integration work, change their environment, build new habits, often combine the experience with ongoing therapy. The medicine cracks something open. What you do with the opening is the actual treatment. If you're considering ibogaine specifically, please understand it carries real risk and should only be undertaken at a facility with proper cardiac monitoring and medical staff. This is not a substance to take in a yurt. The other quiet truth: not everyone is ready. If your life is in acute crisis, if you're actively psychotic, if you're freshly off a benzo taper, the medicine isn't going to fix what stability needs to fix first. Sometimes the most healing thing a good retreat will do is tell you to come back next year. The era when psychedelic healing was something you whispered about is ending. Capital is flowing in. Trials are publishing. The cultural permission slip is being written in real time. That's mostly good for you as someone considering a retreat — better information, more honest conversation, fewer raised eyebrows when you book the flight. Just don't confuse the pharma story with the retreat story. The fact that a biotech firm raised $157 million doesn't tell you anything about whether a particular ayahuasca center in Iquitos is reputable, or whether a psilocybin retreat in the Netherlands is well-run. Those are different questions, answered by different homework. Read facilitator bios. Talk to past participants. Ask about lineage. Ask about screening. Ask about integration. If you're feeling pulled toward this work and want to start comparing actual programs — ayahuasca, psilocybin, ibogaine, San Pedro and others — a curated set of psychedelic and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision. The plants will still be there when you're ready.
The Psychedelic Startup Boom: Who's Actually Building the Future of Plant Medicine
If you've spent any time researching ayahuasca, psilocybin, or ketamine-assisted therapy lately, you've probably noticed something odd. The field used to feel like a whisper network — a friend of a friend who knew a curandero, a quiet retreat tucked into the Dutch countryside, a clinical trial you needed three referrals to enter. Now there are venture-backed startups, telehealth platforms, and biotech labs trying to engineer the next generation of compounds. The money has arrived. So have the spreadsheets. For someone weighing whether to book a psychedelic retreat or try plant medicine for addiction, depression, or just the slow grind of feeling stuck, this matters. The companies getting funded right now will shape what's available to you in the next few years — the protocols, the prices, the credentialing of facilitators, even whether your insurance ever picks up the tab. So it's worth knowing who they are and what they're actually doing. Here's a tour of seven companies that investors have flagged as movers in the space, plus some honest thoughts on what their existence means for people considering a real-life journey. Analysts have thrown around forecasts that the psychedelic treatment market could eventually clear nine figures globally. Whether that number holds or not, the underlying logic is real: depression rates aren't dropping, SSRIs work for some people and fail others, addiction continues to gut families, and the existing mental-health system is buckling. Psychedelics — used carefully, with skilled support — have shown enough promise in clinical trials that smart capital wants in. What that means in practice is a wave of startups doing very different things. Some are trying to design molecules. Some are training therapists. Some are building software for clinics. And a few are doing what humans have done for thousands of years — running retreats with master plants and trained facilitators, just with a website and a Stripe account attached. Based in Boston and founded in 2019, Delix raised north of $100 million working on what they call psychoplastogens — compounds inspired by psychedelics but engineered to skip the trip. The idea is to capture the neuroplasticity benefits (the brain-rewiring part that seems to do a lot of the therapeutic work) without the six-hour experience of ego dissolution. Early animal research suggests these compounds may even reverse cortical atrophy. Whether you find that exciting or vaguely depressing probably says a lot about your worldview. For people who can't take time off work, can't tolerate altered states, or have medical contraindications, a non-hallucinogenic option is genuinely important. For those who believe the mystical experience itself is the medicine, it's a harder sell. Out of Woodstock, New York, Fluence trains psychiatrists, therapists, and social workers in psychedelic-assisted therapy and integration. They raised a modest $3 million seed round, but their work matters disproportionately. The single biggest bottleneck for legal psychedelic therapy isn't the drugs — it's the people qualified to sit with you while you take them. If you've ever wondered why finding a competent psychedelic-informed therapist feels harder than finding a unicorn, this is why. The training pipeline is tiny. Companies like Fluence are trying to fix that. Toronto-based and only a few years old, Homecoming is a digital companion for the period before and after a psychedelic session. Think daily check-ins, journaling prompts, structured integration tasks, and a way for your therapist to see how you're actually doing between appointments. This is the unsexy part of psychedelic work that almost everyone underestimates. The ceremony is loud and dramatic. Integration — the quiet weeks afterward when you're trying to actually change something about your life — is where the work really lands or doesn't. New York-based Journey Clinical built a decentralized model for ketamine-assisted psychotherapy. Your existing therapist — the one who already knows your story — partners with their in-house medical team, who handles eligibility screening, prescribing, and clinical monitoring. You don't have to start over with a stranger to access the medicine. This is one of the more elegant ideas in the space. Continuity of care matters enormously in trauma work, and the standard model of being shuffled to a separate ketamine clinic with a new provider has always felt clinically backwards. Pittsburgh-based and well-funded for a young company, Mindstate is using AI and biochemical data to predict what specific mental states a compound will produce. Their first program is aimed at recreating the empathogenic, MDMA-like state — the warm, connected, defenses-down feeling that has shown such promise for PTSD work. It's ambitious and a little science-fiction. Whether they can actually predict subjective experience from molecular structure is an open question, but the team has impressed people who've looked under the hood. San Francisco-based Osmind is the software backbone for clinics offering ketamine and other psychedelic therapies. It helps practices run, but the long-term value is the data — outcomes data that could eventually convince insurers to cover these treatments, and research data that could refine protocols. Boring on the surface. Probably consequential underneath. Amsterdam-based Synthesis has been around since 2018, running legal psilocybin retreats in the Netherlands and training facilitators. They've adopted a steward-ownership structure — meaning founders and investors are legally bound to the company's mission and social impact, not just returns. That's rare, and it tells you something about how the team is thinking. For readers actually considering a retreat, Synthesis is one of the names that comes up most often in serious conversations about legal, well-organized psilocybin work in Europe. Here's the honest part. None of these companies will sit with you at three in the morning when the medicine is asking you to look at something you've avoided your whole life. That work still happens between you, the plant, and whoever is holding the space. What the industry buildout does change is access. More trained therapists. Better integration support. Clearer information about safety. More legitimate options between the extremes of underground ceremonies with strangers and waiting years for a clinical trial slot. If you're researching plant medicine for addiction recovery, depression, or trauma, the field you're entering today is more navigable than it was even two years ago. A few things that haven't changed and probably won't: Funding announcements are not the same as quality. A startup with $50 million in the bank can still run a mediocre program, and a small lineage-based retreat can offer the most profound experience of your life. When evaluating a retreat, the questions worth asking have less to do with branding and more to do with substance: If a retreat dodges those questions or answers them with marketing language, that tells you something. If they answer them specifically and without defensiveness, that tells you something else. The psychedelic industry is having its moment, and that's mostly good news for people who need help. The molecules, the software, and the venture capital are all interesting — but the actual healing still happens in a room with a person who knows what they're doing. If exploring this further feels right, a curated range of ayahuasca, psilocybin, and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine isn't going anywhere, and neither is the part of you that's asking the question.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Psilocybin and Terminal Illness: What Happens When Mushrooms Meet Mortality
There's a particular kind of dread that arrives with a terminal diagnosis. Not the cinematic kind. The quiet kind — the one that sits at the foot of the bed at 4 a.m. and refuses to leave. For decades, mainstream medicine handed people in that situation a script for SSRIs and a referral to a therapist, and called it a day. It rarely worked. How could it? You're not depressed because your brain chemistry hiccuped. You're depressed because you're dying. This is the gap that psilocybin — the active compound in so-called magic mushrooms — has quietly stepped into over the past decade. Clinical trials at Johns Hopkins, NYU, and Imperial College London have followed terminally ill patients through single high-dose psilocybin sessions and tracked what happens after. The results have been strong enough that even cautious researchers have started using words they normally avoid. Words like profound. Words like lasting. The headline numbers are striking. In one widely cited NYU study, roughly 80% of cancer patients who received a single psilocybin session reported clinically significant reductions in depression and anxiety. Six months later, most of them were still better. That's not a typical outcome for any psychiatric intervention — let alone one delivered in a single afternoon. What's more interesting than the percentages is what the patients say. They don't usually describe feeling less depressed in the way an antidepressant might dull the edges. They describe something more like a shift in vantage point. The fear is still there, but it stops running the show. Death stops feeling like a wall and starts feeling like a doorway, or a horizon, or — in the words of one participant I spoke with — "just the next thing that happens." This is where psychedelics get philosophically slippery. Psilocybin doesn't medicate the sadness. It seems to rearrange the relationship the person has with their own situation. That's a different kind of healing, and one our medical system isn't really built to measure. Conventional antidepressants take weeks to begin working and have to be taken daily, often indefinitely. They blunt mood — both the lows and, frequently, the highs. For someone with months left to live, the math is brutal: spend the remaining time on a medication that may or may not work, that flattens emotional range, and that takes a chunk of those final weeks just to titrate up. Psilocybin works differently. A single session lasts about six hours. The acute effects fade by evening. But the psychological shift — the so-called "afterglow" — can persist for weeks or months. Researchers think this is partly because psilocybin temporarily loosens the brain's default mode network, the system responsible for our habitual self-narratives. When that network goes quiet, people often experience what feels like a direct encounter with something larger than themselves. Call it mystical, call it neurological — the effect on subsequent mood is real either way. For someone facing the end of life, that one afternoon can do work that years of talk therapy didn't touch. This isn't recreational mushroom-taking. In a clinical or retreat setting, the structure is deliberate and the work begins long before any substance is consumed. The integration piece matters enormously. A psychedelic experience without integration is like having a dream you forget by lunchtime. The insight evaporates. Done well, integration turns the experience into something the person can keep referring back to long after the chemical has cleared their system. The terminal-illness research is what put psilocybin back on the cultural map, but it's part of a larger story. Plant medicines and psychedelics are being studied for treatment-resistant depression, alcohol use disorder, tobacco addiction, and PTSD. Ayahuasca and ibogaine — the heavier hitters in this family — have shown remarkable results with opioid and stimulant addiction, areas where conventional rehab has a dismal success rate. What ties these studies together is a theme: psychedelics seem to help with conditions where the person is stuck in a story. Addiction is a story. Depression is a story. Terror of death is a story. None of those stories are wrong, exactly — but they become rigid, and the rigidity is what hurts. Psychedelics, used carefully, appear to make the story negotiable again. This is why master plants like ayahuasca and psilocybin-containing mushrooms have been used ceremonially for thousands of years by cultures who never needed a randomized controlled trial to know what they were doing. The science is catching up to something Indigenous traditions have always understood. If you're reading this because someone you love is facing a terminal diagnosis, or because you're sitting with your own — the honest answer is: maybe. Psilocybin-assisted therapy isn't a cure for death or a guarantee of peace. What it offers is a tool. A door. Whether walking through that door is right for any given person depends on health history, mindset, support systems, and the legal landscape where they live. In the United States, psilocybin remains federally illegal, though Oregon and Colorado have created regulated therapeutic frameworks, and several cities have decriminalized personal use. Outside the U.S., countries like Jamaica, the Netherlands, and Mexico host legal or quasi-legal retreats that work specifically with psilocybin and other plant medicines. Quality varies wildly — and so does safety. If you're considering a retreat, do the unglamorous work first. Ask about medical screening. Ask how many facilitators per participant. Ask what integration looks like and whether it's included. Ask about emergency protocols. A reputable center will have clear answers to all of these. A center that gets defensive when you ask is telling you what you need to know. The most striking thing about the terminal-illness research isn't the symptom reduction. It's that participants, when asked months later, frequently rank the psilocybin session among the most meaningful experiences of their lives — comparable to the birth of a child, or marriage. That's an extraordinary claim for a single afternoon in a quiet room. Whatever you make of it, the conversation around psychedelic healing has moved well past whether these compounds do something. They do. The conversation now is about how to do this carefully, ethically, and in service of the people who need it most. For readers who want to take this further, a range of curated psilocybin and plant-medicine retreats can be browsed on our marketplace here.
Choosing an Ibogaine Clinic: Red Flags Every Seeker Should Know
Here's something nobody puts on the glossy retreat brochure: ibogaine is the most cardiologically demanding psychedelic on the menu. It can also be one of the most effective tools we've got for breaking opioid addiction. Both of those things are true at the same time, and the gap between a good clinic and a careless one is the gap between a life-changing reset and a body bag. That's not hyperbole — it's the actual stakes. If you're researching ibogaine right now, probably because nothing else has touched your addiction or your depression, you deserve a frank conversation about what can go sideways. Not to scare you off plant medicine. To help you choose well. The vast majority of ibogaine deaths in the last twenty years happened at clinics that skipped screening, ran underdosed staff, or treated the medicine like a party drug instead of cardiac-active pharmacology. Knowing what to look for is the single most protective thing you can do. Ayahuasca, psilocybin, San Pedro — these are gentle on the heart compared to ibogaine. Ibogaine, the alkaloid extracted from the root bark of the West African shrub Tabernanthe iboga, blocks a specific potassium channel in cardiac tissue (the hERG channel, if you want the technical bit) and slows your heart's electrical recovery between beats. In a healthy, screened person, that's manageable under medical supervision. In an unscreened person with an undiagnosed long QT interval, electrolyte imbalance, or active opioid still in their system, that same property can trigger a fatal arrhythmia. This is why ibogaine isn't an ayahuasca ceremony with louder drums. It's closer to a hospital procedure with shamanic elements. The medicine itself lasts somewhere between 24 and 36 hours of intense visionary and physical experience, often described as a life review running on fast-forward while the body feels heavy and immobile. People who've been through it tend to come back with a quiet, almost clinical respect for the molecule. It is not a recreational substance, and any operator who treats it like one is already telling you something. The deaths and serious incidents that have made it into medical case reports almost always trace back to the same handful of failures. They're not mysterious. They're preventable. And they keep happening because some operators are running on cash flow, not protocols. Some of these are obvious in retrospect and almost invisible in the moment, especially when you're desperate and the website is beautifully designed. A few patterns to watch for as you scroll through clinic options. They guarantee outcomes. Nobody can promise you'll be cured of addiction, depression, or trauma. Anyone who does is either lying or doesn't understand what they're selling. Good operators talk about probabilities, integration work, and the reality that ibogaine is a window, not a finish line. They downplay the risks. “It's perfectly safe” is a sentence that should make you close the tab. Ibogaine carries real cardiac risk even with perfect protocols. A clinic that won't acknowledge that is either uninformed or hiding something. They want full payment upfront with no medical intake first. Reputable clinics screen you before they accept your money. They will sometimes turn people away — people with certain heart conditions, certain medications, certain psychiatric histories — because giving them ibogaine would be reckless. A clinic that never turns anyone down isn't being inclusive; it's being indifferent. They can't or won't introduce you to past participants. Most legitimate operators are happy to put you on a call with someone who went through their program six months ago. If that request makes them squirrelly, ask yourself why. They're vague about staff credentials. “Experienced team” means nothing. Names, training, years in the work, role during your session — these should be findable. Once you've filtered for the obvious red flags, the real work begins. Here's the workflow I'd suggest to anyone serious about going through with it. For contrast, here's what good looks like. You'll fill out a long intake form covering medical history, psychiatric history, current medications, family history of heart disease, and substance-use history. You'll be asked to get an EKG and bloodwork in your home country before you fly. Some clinics will repeat both on arrival. You'll meet the medical team before you take anything. They'll explain dosing, monitoring, and the emergency protocol in plain language. During the session itself, you'll typically be in a private room with continuous cardiac monitoring — think hospital-style telemetry, not a smartwatch. Staff check on you regularly. A facilitator may sit with you for stretches of the visionary phase. The room is dark, quiet, and physically safe; you won't be wandering around or driving anywhere. Afterward, there's usually a recovery day or two on site before any integration work begins. Good clinics build in time. They don't rush you onto a shuttle the morning after. Integration support varies wildly between operators, and it matters more than most people realize going in. The ibogaine experience often surfaces material the conscious mind has been managing carefully for years. Without someone to help you metabolize it — a therapist, a coach, a peer group, a thoughtful aftercare program — that material can curdle into confusion or relapse instead of clarity. Ask about aftercare specifically. If the answer is hand-wavy, that tells you what you need to know about how the operator thinks about your outcome. Ibogaine is not a miracle. It's a powerful, demanding, occasionally dangerous tool that, in the right hands and the right body, can interrupt patterns nothing else has touched. Opioid addiction in particular responds to it in ways that have caught even skeptical researchers off guard. But the difference between a transformative week and a tragedy is almost entirely about who's running the room and how seriously they take the medicine. Do the research. Ask the awkward questions. Get the EKG even if they don't require one. Talk to people who've been through it. Trust your gut when something feels off, even if the photos are gorgeous and the price is right. Plant medicine attracts beautiful storytellers and careful clinicians in roughly equal measure, and you need the second kind for this particular molecule. For readers who want to take the next step, a range of vetted ibogaine and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, decide it with your eyes open — that's the part of the process no one else can do for you.
Kambo Safety: The Real Risks Behind the Frog Medicine Trend
A woman in her late thirties walks into a sharehouse on the north coast of New South Wales. She's there to sit for kambo — the secretion of an Amazonian tree frog, dabbed into small burns on her skin. She's done it before. She trusts the woman administering it. A few hours later she's dead on the floor, and her housemate is on the phone to triple-zero because the person running the ceremony doesn't know the number and doesn't own a phone. That's not a hypothetical. That's the case the NSW state coroner ruled on, and the findings should be required reading for anyone thinking about kambo, ayahuasca, or any plant medicine ceremony run outside the bounds of medical oversight. The coroner's language was unusually direct: vulnerable people are putting their trust in self-styled healers who don't have basic first aid training, and the risks of kambo are being underestimated by the people promoting it. If you're reading this because you're weighing a retreat, or because a friend has been raving about how kambo changed their life, slow down. This one's worth thinking through. Kambo is the waxy secretion of Phyllomedusa bicolor, the giant monkey frog of the Amazon basin. Indigenous groups in the region — the Matsés, Katukina, Yawanawá and others — have used it for generations, traditionally before hunting, to sharpen the senses and clear what they describe as panema, a kind of bad luck or heaviness. The frogs are tied to sticks, their backs scraped, and the dried secretion is later applied to small burns on the skin of the recipient. What happens next is intense and fast. Within seconds of application, the peptides in the secretion hit the bloodstream. Blood pressure crashes or spikes. The face swells. People vomit, sometimes violently. There can be diarrhea, sweating, racing heart, panic, a sense of overwhelming heat. The acute phase is usually short — twenty to forty minutes — but those minutes are not gentle. In the West, kambo has been folded into the broader neo-shamanic scene and marketed as a deep physical and spiritual cleanse. You'll see claims about boosting the immune system, clearing addiction, treating depression, even helping with cancer. Here's the part the coroner was explicit about: there is no credible research supporting those medicinal claims. There is, however, documented evidence of harm. Kambo contains a cocktail of bioactive peptides — dermorphin, deltorphin, phyllomedusin, phyllokinin, sauvagine and others. Some are being studied for legitimate pharmaceutical reasons. But the dose in a ceremony isn't measured. The peptide concentration varies frog to frog, batch to batch, practitioner to practitioner. You don't know what you're getting. The physiological strain is real. Kambo can trigger severe hyponatremia (low sodium) if practitioners encourage the loading of water beforehand — a practice that has killed people. It puts stress on the cardiovascular system. It can interact dangerously with prescription medications, particularly antidepressants and blood pressure drugs. People with cardiac conditions, epilepsy, recent surgeries, or who are pregnant should not go near it. And here's the thing — most ceremony providers don't do a serious medical screen. They ask a few questions. They take your word for it. Adverse events documented in the medical literature include seizures, psychosis, kidney injury, esophageal tears from violent vomiting, syndrome of inappropriate antidiuretic hormone secretion, and sudden cardiac death. The Australian Therapeutic Goods Administration eventually classified kambo as a Schedule 10 poison — the most restrictive category, meaning substances of such danger to health that their sale, supply and use should be prohibited. That's not a regulator being squeamish. That's a regulator looking at a death toll. The deeper problem the coroner pointed at isn't kambo itself — it's the parallel economy of self-credentialed healers, priestesses, maestras and shamans that has grown up around plant medicines in the last two decades. Someone takes a two-week course online, designs a website, picks a Spanish or Quechua honorific, and starts charging for ceremonies. This isn't gatekeeping for its own sake. Indigenous traditions that work with kambo, ayahuasca, or peyote involve years of apprenticeship, often a lifetime, with extensive teaching about dosage, contraindications, energetic management, and crucially what to do when something goes wrong. A two-week certificate doesn't replicate that. Neither does charisma. Neither does a beautiful altar. The case in NSW is bleak on this point. The person administering kambo at the fatal ceremony admitted she didn't know the emergency number. She didn't have a phone. The recipient herself had just completed a short practitioner course and was, on the day, leading the session. Two people, neither equipped for what was about to happen, in a sharehouse, with no medical backup. The result is exactly what you'd expect when you remove every safeguard. None of this means every retreat is a death trap. Reputable plant medicine retreats — including ayahuasca centers in Peru, ibogaine clinics in Mexico, and psilocybin retreats in the Netherlands and Jamaica — operate with screening protocols, medical staff on site, and clear emergency procedures. They're not hard to identify if you know what you're looking for. Some questions worth asking any retreat or practitioner before you hand over money: If the answers are vague, defensive, or wrapped in spiritual language designed to make you feel like asking is beneath the work — walk away. A serious practitioner welcomes those questions. They've thought about them more than you have. It would be easy to read a story like this and decide all plant medicine is reckless. That's not quite right either. Ayahuasca, psilocybin, ibogaine, and other psychedelic substances are being studied with increasing seriousness for addiction, treatment-resistant depression, PTSD, and end-of-life anxiety. Some of the early clinical data is genuinely promising. People do find their lives reorganized by these experiences in ways they couldn't access through talk therapy alone. But the gap between a well-run clinical or ceremonial container and a sharehouse ritual run by an under-qualified practitioner is enormous. The medicine isn't the only variable. Set, setting, screening, dosage, facilitation, and aftercare matter as much as the substance itself — often more. The deaths and serious injuries that make headlines almost always involve a breakdown somewhere along that chain, not the molecule acting alone. Kambo is a particular case because the claimed benefits are largely unsupported by research while the physiological risks are well documented. That's a worse risk-benefit profile than most of the classical psychedelics. If you're drawn to the idea of a deep cleanse or a hard reset, there are safer roads to walk down — including ones that involve less dramatic medicines or none at all. The woman at the center of the coroner's findings was, by every account, kind, smart, in pain, and looking for a way through. That's most of the people I meet at retreats. The pull toward plant medicine isn't usually about thrill-seeking — it's about real suffering and the sense that conventional options have run out. That's a sympathetic, human place to be. It's also a place where you're easy to take advantage of. Pain makes us bad consumers. We grasp at the first practitioner who speaks the right language, lights the right candles, says the right things about our wounded inner child. The work of choosing well — slowly, with skepticism intact — is part of the medicine itself. Maybe the first part of it. If you're researching plant medicine because something in your life is genuinely stuck, take the time to do it properly. Read inquest findings. Read peer-reviewed studies. Talk to people who've sat with the practitioner you're considering, ideally years after their ceremony, not weeks. And if you do want to explore vetted ayahuasca, psilocybin, or other plant medicine retreats with proper screening and integration support, you can browse our marketplace here and compare options without the pressure. The medicine isn't going anywhere. Take your time.
Inside a Santo Daime Feitio: How Ayahuasca Is Brewed in Brazil
It was past two in the morning when the smashing started. The ceremony in the temple had ended an hour earlier, and now eight people were standing around tree stumps fixed into the dirt floor of a wooden shed, pounding macerated vine with wooden clubs in a rhythm that matched the hymns being sung — without pause — somewhere off in the dark. The fire under six enormous pots crackled steadily. Logs kept arriving. No one looked tired in the way you'd expect. This is a feitio, the labor-intensive making of ayahuasca as it's practiced in the Santo Daime tradition of Brazil. If you've been researching ayahuasca retreats and only know the brew as something handed to you in a small cup at the start of a ceremony, the feitio is the part of the story most outsiders never see. It's where the medicine actually comes from — and the part that, more than any other, tells you what kind of culture you'd be stepping into. Santo Daime is a Brazilian religion founded in the early 20th century by Mestre Irineu, a tall Afro-Brazilian rubber tapper who, according to the tradition's own lore, received the recipe for the sacrament through a vision in the Amazon forest. The brew is called daime — from the Portuguese for “give me” — and it's made from the same two plants that produce ayahuasca in most other Amazonian traditions: the jagube vine (Banisteriopsis caapi) and the leaves of chacruna (Psychotria viridis), which Santo Daime members affectionately call rainha, the queen. The chemistry is the same chemistry that underlies every ayahuasca ceremony anywhere. The vine contains beta-carbolines — harmine and its relatives — which switch off the monoamine oxidase enzyme in your gut long enough for the DMT in the chacruna leaves to survive digestion and reach the brain. Without one, the other does nothing. That's the entire trick. Two plants, two roles, one brew. What makes Santo Daime distinct isn't the pharmacology but the framing. The making of the medicine is itself a ceremony. Hymns are sung continuously while the work happens. Volunteers — including women and children, depending on the task — participate at every stage, from harvesting leaves to scrubbing pots. There's a job for everyone, and the brew you eventually drink in ritual is, in a real sense, something the community has built together with their hands. The first major task of any feitio is the bateção — the smashing. The jagube vine arrives in thick, woody braids that have to be opened up so the active compounds can leach into the water. Mechanized chopping is used in some places now, but at the temple in Minas Gerais where I'm describing, it's done barefoot, on tree-stump anvils, with wooden clubs. You strike the vine until the wood splits into fibers as fine as hair. The rhythm matters. The work is paced to hymns that go on for hours, and the strikes fall into the cadence whether you intend them to or not. By four in the morning your shoulders ache and your palms have gone numb, and somehow you're still going, because the song hasn't stopped and the pile of vine hasn't shrunk as much as you'd hoped. The smashed vine gets layered into 120-liter pots with the chacruna leaves — seven alternating layers per pot, beginning with a bed of coarse vine fibers at the bottom so the green leaves don't touch the hot metal and scorch. A typical pot takes around 40 kilograms of vine, 8 kilograms of leaves, and 60 liters of water. Then it cooks. For hours. The liquid reduces to roughly half its volume, turning a darker yellow-brown, and is drained through a metal gutter into clean containers. Here's something most articles about ayahuasca skip over: at this stage, what you've made isn't yet considered daime. It's just a concentrated tea. To become sacrament, the liquid from the first two pots gets poured into a third — assembled with the best of the remaining vine and the most carefully selected leaves — and reduced again over the fire. Only after that second cooking is the brew considered finished. The pots always come in multiples of three, which has both practical and symbolic weight depending on whom you ask. Straight from the drainer, still hot, the brew tastes more like tea than the bitter, fermented liquid most people associate with ayahuasca. The golden color is genuinely pleasant. The bitterness people complain about in ceremonies tends to come from time in the bottle — the brew keeps fermenting if it isn't packaged hot and sealed tight. Working through the night, drinking small cups of fresh daime to stay alert, the crew shifts between focused labor and something closer to ceremony. People sing. They joke. Then someone catches a particular phrase in a hymn and the room goes quiet for a verse or two before the clubs start again. The original recipe, as Mestre Irineu reportedly received it, would have ended at this point. The leftover plant matter would be discarded. The resulting brew is what daimistas call first-degree daime. But chacruna and jagube don't grow on demand, and as the religion spread out from its Amazonian heartland, the elders had to adapt. Padrinho Sebastião, who took over after Irineu's death, decided to cook the used material a second time, with fresh water, in another set of three pots. The result is second-degree daime. His son Padrinho Alfredo pushed further — third degree, fourth degree, and so on. Each subsequent extraction is weaker per pot, but the leftover material still has something to give. Then there's a different practice: mixing daimes of different degrees together and cooking new batches with extra chacruna leaves added in. This is where you start hearing terms like: The naming convention is just math: how much original liquid went into how much finished brew. But the experiential difference between them is significant. A 5:1 is not just a stronger sip of a 3:1; it's a different ride, with a different purpose in the ritual life of the community. You're probably not reading this because you want to enroll in a Santo Daime church. You're reading because you're weighing whether plant medicine — and an ayahuasca retreat in particular — is worth taking seriously. Here's what the feitio tells you, even from a distance. First, ayahuasca traditions are not interchangeable. Santo Daime is one branch — hymn-based, Christian-inflected, communal, ritualized around dancing in formation. The Shipibo lineages of Peru work differently, with icaros sung individually over each participant. The União do Vegetal is another distinct Brazilian tradition. Vegetalista curanderos in the upper Amazon run yet another model. When a retreat says it offers “ayahuasca ceremonies,” ask which tradition it draws from, and how the medicine itself was made. Second, the question of who brewed your daime — and how — is not a small detail. In serious traditions, the medicine carries the intention and care of the people who made it. A retreat that buys brew from an unknown source is materially and ethically different from one where you can ask to see the kitchen. You don't need to be a purist about this, but you should know which kind of operation you've signed up for. Third — and this is the part I'd most want a friend to hear before booking anything — ayahuasca is sometimes pursued as a tool for healing from addiction, depression, trauma, or stuck patterns. It can absolutely play a role. But it works best inside a culture, with people who know what they're doing, who follow a recipe handed down from someone who followed a recipe handed down from someone else. The feitio is a reminder that this medicine has a context. Take that context seriously and the experience tends to take care of itself. After two nights and a long final day at the Heaven of the Divine Star, the work produced roughly 140 liters of daime. It was bottled hot and sealed quickly to slow fermentation. Some of it was served at the closing ceremony — a bailado, a dancing ritual that can last hours. Participants stay inside rectangles painted on the floor, stepping always to the left first, moving through the three permitted rhythms: march, waltz, mazurka. From the outside, someone described it as the back-and-forth motion of a gear. From the inside, with the daime moving through you and a hymn rising from sixty voices at once, it's harder to describe and easier to feel. If anything about this glimpse into the tradition has nudged you toward exploring further, a range of vetted ayahuasca retreats — including ones in Brazilian and Amazonian lineages — can be browsed on our marketplace here. Go slowly. Ask the questions you need to ask. The medicine has been around a long time, and so have the people who know how to hold it.
Microdosing Psychedelics: What the Science Actually Says So Far
Walk into any co-working space in Berlin, Austin, or Lisbon and you’ll probably bump into someone quietly convinced that a sliver of psilocybin every third morning is the reason they finally stopped doomscrolling and started writing again. Microdosing has crossed from Silicon Valley curiosity into something your accountant might mention over brunch. But underneath the chatter — the books, the podcasts, the carefully labeled tincture bottles — sits a stubborn question: does it actually work, or are people just feeling good about feeling like they’re doing something? The honest answer, after a decade of renewed psychedelic research, is somewhere between “maybe” and “we genuinely don’t know yet.” If you’re researching microdosing as a possible path through depression, addiction, creative stagnation, or the general flatness of modern life, you deserve a real look at the evidence — not the breathless version, and not the dismissive one. A microdose is a fraction of a recreational dose — roughly one-tenth to one-twentieth of what someone would take to have a full psychedelic experience. With psilocybin mushrooms, that usually lands around 0.1 to 0.3 grams of dried fruiting body, compared with the 2 to 3 grams that produce a proper journey. With LSD, the territory is somewhere between 8 and 15 micrograms versus a recreational 100 micrograms or more. The point is that you don’t feel the substance in any classic psychedelic sense. No visuals. No ego dissolution. No couch-melting. That subperceptual quality is the whole pitch. Practitioners report a subtle lift in mood, sharper focus, more empathy with the people around them, occasionally a kind of background creative hum. The protocols vary — James Fadiman’s famous one-day-on, two-days-off schedule is probably the most cited — and most people cycle for four to eight weeks, then pause. Here’s the problem with all of that, scientifically speaking: there is no single agreed definition of a microdose, mushroom potency varies wildly from flush to flush, and LSD is a tasteless, invisible compound whose dose you can only trust if your source is impeccable. Researchers studying this stuff are essentially trying to measure something that hasn’t been standardized yet. The studies pull in two directions, and that’s worth sitting with rather than glossing over. On the optimistic side, a number of large observational studies — including one that tracked roughly 950 psilocybin microdosers against a non-dosing control group over thirty days — have found small-to-medium improvements in mood, anxiety, and general mental health, fairly consistent across age, gender, and whether or not someone walked in with a mental-health diagnosis. That sounds promising, and it lines up with the thousands of anecdotal reports floating around the internet from people who swear it pulled them out of a funk. On the skeptical side, the moment you tighten the methodology, the effect tends to shrink or vanish. In one randomized controlled trial, researchers gave half the participants real psilocybin and half a placebo. Subjectively, the dosing group reported feeling happier and more creative. Some even showed measurable changes on EEG. But on objective measures of creativity, cognition, and well-being? No meaningful difference from placebo. That gap — between how people feel and what tests can actually detect — is the central puzzle. There are two reasonable interpretations: Both can be partly true. Placebo is not nothing — it’s one of the most powerful forces in medicine. But “you’re just imagining it” is a thinner explanation than it sounds when thousands of people are reporting similar shifts. Short-term, low-dose psilocybin appears to be physiologically gentle. Indigenous communities have worked with these mushrooms for centuries. There’s no evidence of organ toxicity at these doses, no addictive pull in the way alcohol or opioids grab people, and the acute risks of a microdose are minimal because you’re not actually having a psychedelic experience. That said, the safety picture isn’t clean, for a few specific reasons: And then there’s the legal layer. In most of the United States and Europe, psilocybin and LSD remain controlled substances. Oregon and a handful of cities have shifted ground, and Colorado is moving in a similar direction, but possession charges are still very real. That alone is a reason a lot of people who would otherwise experiment instead choose to travel — to a legal jurisdiction, to a supervised setting, to a place where the substance is the medicine, not the legal liability. Here’s the part that doesn’t get said enough: most of the impressive clinical results we’ve seen for psychedelics in the last decade — for treatment-resistant depression, PTSD, end-of-life anxiety, alcohol use disorder, tobacco cessation — came from full doses, not microdoses. Big, immersive, sometimes difficult sessions, usually with trained facilitators present. That’s where the headline numbers live. Microdosing is, in a sense, a much more modest proposition. It’s the daily multivitamin to ceremony’s open-heart surgery. If you’re looking for genuine, structural shifts in addiction patterns or deeply rooted depression, the evidence so far points toward higher-dose, supported experiences rather than a sprinkle every Monday and Thursday. That doesn’t mean microdosing is worthless. It may genuinely help some people maintain or extend the benefits of a full experience. It may be useful for milder mood concerns. It may simply be a low-stakes way for someone to introduce psychedelics into their life. But conflating the two — assuming microdosing offers what a ceremonial dose offers, just slower — is a misread of the science. A few practical points, said plainly: On that last point — if what you’re really chasing is meaningful change rather than a productivity tweak, a properly held ceremony with experienced facilitators tends to be where the real work happens. For readers who want to take that further, a range of curated psilocybin and plant-medicine retreats can be browsed on our marketplace here. The science of microdosing will sharpen over the next few years, and the legal landscape is shifting faster than most people realize. For now, somewhere between the evangelists and the debunkers sits the most useful posture: curious, careful, and genuinely willing to admit that we don’t yet know what we think we know.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
